NCI-H929細(xì)胞，人骨髓瘤細(xì)胞株

簡要描述：NCI-H929細(xì)胞，人骨髓瘤細(xì)胞株
原代細(xì)胞|細(xì)胞系|細(xì)胞株|菌種；細(xì)胞庫管理規(guī)范，提供的細(xì)胞株背景清楚，提供參考文獻(xiàn)和*培養(yǎng)條件！

產(chǎn)品型號：CRL-9068
廠商性質(zhì)：生產(chǎn)廠家
更新時間：2024-11-21
訪問量：1860

產(chǎn)品咨詢聯(lián)系我們

產(chǎn)品分類

Product Category

細(xì)胞庫

細(xì)胞原代牛、狗、雞、鴨、魚原代細(xì)胞羊原代細(xì)胞豬原代細(xì)胞兔原代細(xì)胞小鼠原代細(xì)胞大鼠原代細(xì)胞人原代細(xì)胞培養(yǎng)基原代細(xì)胞凍存液 ATCC 人乳腺癌豬正常細(xì)胞豬睪丸細(xì)胞系人膠質(zhì)瘤細(xì)胞人成骨細(xì)胞人永生化肝細(xì)胞人肝癌細(xì)胞人卵巢癌細(xì)胞人結(jié)直腸腺癌人經(jīng)典小細(xì)胞肺癌細(xì)胞人小細(xì)胞肺癌細(xì)胞人結(jié)直腸腺癌細(xì)胞人鼻腔上皮細(xì)胞中國倉鼠卵巢懸浮細(xì)胞嗜性逆轉(zhuǎn)錄病毒包裝穩(wěn)定細(xì)胞株小鼠神經(jīng)細(xì)胞瘤人眼脈洛膜黑色素瘤 PT67 逆轉(zhuǎn)錄酶病毒包裝細(xì)胞鴨子胚胎成纖維細(xì)胞豬腎細(xì)胞系昆蟲細(xì)胞貓腎細(xì)胞恒河猴胚腎細(xì)胞倉鼠卵巢細(xì)胞負(fù)鼠腎細(xì)胞倉鼠肺細(xì)胞果蠅胚胎細(xì)胞家貓肺成纖維樣細(xì)胞雞胚細(xì)胞豚鼠心肌來源細(xì)胞豚鼠肺成纖維樣細(xì)胞豚鼠皮膚成纖維樣細(xì)胞狗腎細(xì)胞非洲綠猴胚胎腎上皮細(xì)胞猴胚胎腎上皮細(xì)胞長臂猿淋巴瘤新生牛眼囊成纖維細(xì)胞黑化大家鼠肺成纖維樣細(xì)胞俄勒岡地鼠細(xì)胞家兔皮膚成纖維樣細(xì)胞昆蟲卵巢細(xì)胞人胸膜瘤細(xì)胞非洲綠猴腎細(xì)胞 VERO 衍生株（SVP）白化金黃地鼠肺成纖維樣細(xì)胞黃胸鼠肺成纖維樣細(xì)胞白鰱尾鰭細(xì)胞蝙蝠肺細(xì)胞草魚腎細(xì)胞系大黃魚腎細(xì)胞猴腎細(xì)胞系犬腎細(xì)胞系人結(jié)腸直腸腺癌豬肺泡巨噬細(xì)胞 PFHSA05（TLL2）人重組特洛德樣蛋白因子 PFHSA04 （BMP1）人重組骨誘導(dǎo)因子人乳腺癌細(xì)胞結(jié)腸癌細(xì)胞成纖維細(xì)胞人胚腎細(xì)胞動物卵巢細(xì)胞動物胚胎細(xì)胞動物肺細(xì)胞肋骨來源細(xì)胞成纖維樣細(xì)胞動物上皮細(xì)胞動物肝臟細(xì)胞可誘導(dǎo)表達(dá)穩(wěn)定細(xì)胞株動物氣管細(xì)胞動物腎細(xì)胞動物巨噬細(xì)胞人正常細(xì)胞人腫瘤細(xì)胞、癌細(xì)胞小鼠正常細(xì)胞小鼠腫瘤細(xì)胞、癌細(xì)胞大鼠正常細(xì)胞大鼠腫瘤細(xì)胞其它動物細(xì)胞查看全部產(chǎn)品

相關(guān)文章

詳細(xì)介紹

NCI-H929細(xì)胞，人骨髓瘤細(xì)胞株

ATCC^® Number:

CRL-9068™

Price:

$309.00

Designations:	NCI-H929 [H929]
Depositors:	National Cancer Institute
Isotype:	IgA kappa (Recent tests for IgA, kappa have not detected the production of IgA; the cells are producing kappa light chain.)
Biosafety Level:	1
Shipped:	frozen
Medium & Serum:	See Propagation
Growth Properties:	suspension
Organism:	Homo sapiens (human)
Morphology:	lymphoblast
Source:	Organ: bone marrow Disease: plasmacytoma; myeloma Cell Type: B lymphocyte;
Permits/Forms:	In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
NCI-H929細(xì)胞，人骨髓瘤細(xì)胞株
Receptors:	transferrin
Antigen Expression:	PCA-1; CD38 +
DNA Profile (STR):	Amelogenin: X CSF1PO: 11 D13S317: 12 D16S539: 9,13 D5S818: 11,12 D7S820: 10,12 THO1: 9.3 TPOX: 8,11 vWA: 14,15
Cytogenetic Analysis:	Near tetraploid. Most copies of chromosome 8 have the 8q+ abnormality.
Age:	62 years
Gender:	female
Ethnicity:	Caucasian
Comments:	This cell line was established from a malignant effusion in a patient with myeloma. The cells are positive for plasma cell antigen 1 (PCA-1), transferrin receptor, CD38 (T10), but are negative for HLA DR, CALLA and markers of early B cell development. They are negative for Epstein-Barr virus nuclear antigen (EBNA). The cells have a rearrangement of the c-myc proto oncogene and express c-myc RNA. There is also an activated ras allele.
Propagation:	ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: 2-mercaptoethanol to a final concentration of 0.05 mM; fetal bovine serum to a final concentration of 10%. Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C
Subculturing:	Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 4 X 10(5) viable cells/ml. Interval: Maintain cultures at cell concentrations between 5 X 10(5) and 1 X 10(6) viable cells/ml. Medium Renewal: 2 to 3 times per week
Preservation:	Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase
Related Products:	Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001 recommended serum:ATCC 30-2020
References:	22372: Hollis GF, et al. Complex translocation disrupts c-myc regulation in a human plasma cell myeloma. Mol. Cell. Biol. 8: 124-129, 1988. PubMed:3275865 23349: Gazdar AF, et al. Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene. Blood 67: 1542-1549, 1986. PubMed: 2423157 23351: Ernst TJ, et al. Identification of a second transforming gene, rasn, in a human multiple myeloma line with a rearranged c-myc allele. Blood 72: 1163-1167, 1988. PubMed: 3048435